



INVESTOR PRESENTATION

WITH 3Q 2023
FINANCIALS

(Cboe CA:VRNO)
(OTCQX:VRNOF)

Geographic footprint data as of 02.15.2024.

BEFORE WE BEGIN

Forward-Looking Information

This presentation contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and also contains statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Verano Holding Corp.'s (the "Company") beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "strategies", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein include, but are not limited to statements or information with respect to the Company's position in the marketplace, proposed budgets and guidance, the proposed completion or buildout of Company facilities, the Company's cultivation capacity, the accretive nature of acquisitions, the fortification of the Company's presence in core markets, the possibility of material organic expansion, delivery of shareholder value and the ability to maintain industry-leading margins and add depth to leadership.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and forward-looking statements herein, including, without limitation, the risk factors discussed in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.com/edgar, including, without limitation, the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2022 and subsequent quarterly reports on Form 10-Q for 2023. The forward-looking information and forward-looking statements contained in this presentation are made as of the date of this presentation, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

BEFORE WE BEGIN

Non-GAAP Financial Measures

This presentation refers to certain non-GAAP measures to evaluate the performance of the Company. The terms “EBITDA”, “Adjusted EBITDA”, “Adjusted EBITDA Margin” and “Free Cash Flow” do not have any standardized meaning prescribed within U.S. Generally Accepted Accounting Principles (“GAAP”) and therefore may not be comparable to similar measures presented by other companies. Such measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. EBITDA is calculated herein as Net Income (Loss) before interest expense, income tax expense, depreciation, and amortization. The Company presents EBITDA on a consistent basis from period to period. Adjusted EBITDA is calculated herein as Net Income (Loss) attributable to the Company plus net interest expense, income tax expense, depreciation and amortization, and also excludes certain one-time items. Adjusted EBITDA Margin is calculated herein as Adjusted EBITDA divided by Revenue. Free Cash Flow is calculated herein as Net Cash Provided by Operating Activities minus Capital Expenditures. Management believes that these non-GAAP financial measures provide useful information to readers as a supplement to reported GAAP financial information because these measures provide consistency and comparability with past financial performance and assist in comparisons with other companies, some of which use similar non-GAAP information to supplement their GAAP results. Management reviews these non-GAAP financial measures on a regular basis and uses them to evaluate and manage the performance of the Company's operations. These measures should be evaluated only in conjunction with the Company's comparable GAAP financial measures and reconciliations of each non-GAAP measure to its most directly comparable GAAP measure can be found on our website at investors.Verano.com and in the appendix of this presentation.

VERANO AT A GLANCE	5
OUR FOOTPRINT	7
THE CASE FOR VERANO	10
HOUSE OF BRANDS	15
3Q 2023 FINANCIALS	35
APPENDIX	41



VERANO AT A GLANCE

VERANO™

EST.
2014



**12+
BRANDS**



**3,700+
EMPLOYEES**



**13
STATES**




**138 OPERATING
RETAIL LOCATIONS**



14 FACILITIES
CULTIVATION &
PRODUCTION FACILITIES
SPANNING **1M+ FT²**



**120M+ AMERICAN
ADULT POPULATION**
WITHIN GEOGRAPHIC
FOOTPRINT



**~700 ACTIVE
WHOLESALE
ACCOUNTS**



**>140
PLANNED RETAIL
LOCATIONS**

OUR FOOTPRINT














VERANO™



OUR FOOTPRINT



SCALABLE PLATFORM

													
State	IL	FL	AZ	NJ	PA	NV	MD	CT	OH	MA	MI	WV	AR
Population	13M	22M	7M	9M	13M	3M	6M	4M	12M	7M	10M	2M	3M
Medical/ Adult Use	Both	M	Both	Both	M	Both	Both	Both	M	Both	Both	M	M
# Dispensaries	10	74 <i>With Additional Openings Planned</i>	6	3	18	5	4	4 <i>With 4 Additional Openings Planned</i>	5	2	1	5 <i>With Option to Open 2 More</i>	1
Facility Size	192k ft ²	262k ft ²	62k ft ²	120k ft ²	62k ft ²	42k ft ²	38k ft ²	217k ft ²	22k ft ²	26k ft ²	n/a	40k ft ²	n/a
Cultivation?	X	X	X	X	X	X	X	X	X	X		X	
Processing?	X	X	X	X	X	X	X	X	X	X		X	
Location(s)	Albion	Apollo Beach & Palatka	Coolidge & Winslow	Branchburg	Chester & Upland	North Las Vegas	Jessup	Rocky Hill	Canton	Sharon	n/a	Beaver	n/a

THE CASE FOR VERANO



THE CASE FOR VERANO

PEOPLE

Entrepreneurial spirit

Culture of diversity & inclusion

Long average tenure

Cannabis advocacy

PROCESS

Operator's mindset. Stringent SOPs.
All about efficiency.

Hospitality-driven

Extensive R&D

Leverage leading-edge
production automation

PRODUCT

Leading genetics

Premium flower & proprietary strains

Comprehensive CPG brand offering

Products cover nearly all formats
& formulas

OPERATIONAL EXCELLENCE **THROUGH VERTICAL INTEGRATION**

Balanced approach reduces over-reliance on any single wholesaler or retailer.

Vertically integrated in **11 of 13** markets.



GEOGRAPHIC OVERVIEW

CULTIVATION & PRODUCTION

14

Cultivation &
production facilities

RETAIL SPACES

138

Operational locations
across 13 states

M&A STRATEGY

A DELIBERATE APPROACH

- **Grow within states** identified to have high likelihood to pass recreational use
- **Seek well-performing stores** with potential for continued enhancement from integration
- **Look for teams** that are willing to stay on board and continue as strong operators
- **Target attractive 2024 EBITDA multiples**



TERRITORY



NSE



AK | AGRI-KIND

AGRONOMED
BIOLOGICS



HOUSE OF BRANDS

Extensive portfolio of **trusted** consumer products





VERANO™

VERANO™

RESERVE

Our namesake brand, Verano offers a curated collection of coveted genetics - covering classic fan-favorites, the latest trends, and proprietary strains that are cross-bred and pheno-hunted in-house. The vast genetic offering expands into several marquee product lines including premium whole bud flower, pre-rolls, live vapes and concentrates.

VERANO™



The essence





*The
Essence*

TIME IS PRECIOUS, MAKE IT COUNT

Embrace the possibilities of every moment through (the) Essence. Whether you're looking to unwind after a long day; to soothe or sleep; to get active or creative; all are best done with a present mind. Our genetics are carefully selected, bred and pheno-hunted to deliver a spectrum of experiences, each intended to enrich the everyday.

Sandy

45 rpm
A
MATTING - CLIVE MAX (12:30)
RECORDS
LONG



Savvy

MORE FOR LESS

Shaped by passion for grassroots cannabis culture, Savvy represents the new age for street smart aficionados who want more for less. Stay wallet smart with disposable pens, 1g cartridges and bulk flower, so you can blaze on without breaking the bank. In a world full of filters, be yourself... be Savvy.



BITS





**LOW DOSE.
HIGH FUNCTION.
ALL DELICIOUS.**

Bits are the everyday cannabis consumable intended to enhance, not overtake. A gentle alternative to indulging without overdoing it. Each bit contains 5mg of THC and a dash of adaptogens, with tailored varieties that add CBD, CBN, or CBG so that you can do more with less.

ENG ORE

EDIBLES





ENCORE

LET THE SHOW GO ON

VERANO™

Like a song that takes you back, Encore Edibles are all timeless hits. Finding comfort in the familiar, these terpene-enriched treats come in classic flavor profiles, reminiscent of your old-school favorites.



Avexia[™]
of the elements



Avexia™

HIGHER WELLNESS

Avexia, meaning "wellness" in Greek, offers product made to effortlessly enhance any self-care routine. Carefully formulated with cannabinoids and other natural ingredients, Avexia harnesses the power of the elements to deliver you the ultimate dose of relief in a range of topicals, tablets, tinctures and RSO.

ON THE ROCKS



ON THE ROCKS
LIVE ROSIN BADDER
THE BERRY COLLECTION

LIVE ROSIN BADDER
ON THE ROCKS
THE BERRY COLLECTION

ON THE ROCKS
LIVE ROSIN BADDER
THE BERRY COLLECTION

ON THE ROCKS
LIVE ROSIN BADDER
THE BERRY COLLECTION
LIGHT PRESS
HASH ROSIN



HERITAGE, REDEFINED.

On The Rocks is a cannabis collection defined by solventless extraction methods that date back thousands of years. Dry sift and ice water capture the essence of flower by collecting its cannabinoid- and terpene-rich trichomes. These trichomes are then refined in small batches and hand-crafted to extract the purest expression of the plant. No solvents or embellishments...it's cannabis, On The Rocks.

VERANO™





müv™



FLORIDA'S FINEST

MÜV makes cannabis-based medicine. In awe of the healing powers of this plant, we tapped top cannabinoid scientists and researchers to develop the MÜV medicinal cannabis line. Fueled by expertise, ingenuity, and a relentless dedication.

VERANOTM



EXPANDING RETAIL PRESENCE





Zen Leaf™ aspires to be the most influential cannabis retail brand, and to command brand loyalty of a myriad of cannabis consumers.

Inspiring our customers drives our mission to capture people's imaginations, satisfy deep and important life needs, and offer unparalleled innovative products underpinning our economic success and cultural influence in an increasingly crowded marketplace.

- Custom store designs provide an edge in the market and create an environment that satisfies the myriad of patron needs through reliability, accessibility, and authenticity
- Superior customer service
- Aggressive expansion underway with existing states and across our broader license footprint



- 74 operational retail locations in Florida
- State-of-the-art dispensaries offering an extensive selection of award-winning products
- Offers a suite of in-house brands including MÜV, Verano Reserve, Savvy, and Sweet Supply
- One of the widest selections of concentrates for patients needing macro-dosing options
- Knowledgeable and friendly staff dedicated to helping medical patients

3Q 2023 FINANCIALS

VERANO™




A TOP COMPETITOR WITH STRONG GROWTH

- Top 5 MSO by revenue
- Experiencing rapid growth (organically and through M&A)
- Our scale allows for operational efficiencies, more profitable cultivation and the ability to quickly adapt to changing legislation

THE CANNABIS INDUSTRY'S LEADING ADJUSTED EBITDA¹ PROFILE

FY 2022 Adjusted EBITDA Margin²



¹Adjusted EBITDA Margin is a Non-GAAP number the Company defines as income attributable to the Company plus net interest expense, income taxes, depreciation and amortization, and also excludes certain one-time items. Reconciliation for Adjusted EBITDA can be found in past quarterly financial results at investors.verano.com in the Newsroom. ²Peer set includes the largest MSOs by revenue.

3Q 2023 FINANCIAL RESULTS

- Retail / wholesale revenue split of 67% / 33% for the quarter¹
- \$10M of 3Q 2023 CAPEX fully funded by operating cash flow
- Generated \$27M of Free Cash Flow² in 3Q 2023 and \$51M YTD

\$USD thousands	3Q 2023 Results
Revenue	\$240,088
Gross Profit	\$133,220
Income from Operations	\$40,288
Net Loss	\$(17,842)

FORTIFYING THE BALANCE SHEET

- Holding \$130M cash for flexibility
 - Evaluating best use of excess cash with plans to deploy it in manners that maximize shareholder value
- Made \$115M in tax payments year to date

\$USD thousands	As of September 30, 2023
Cash	\$129,921
Total Assets	\$2,355,103
Debt	\$422,179
Total Liabilities	\$1,041,618



LEGISLATIVE OUTLOOK

Encouraged by HHS Announcement

On August 30, 2023, the Department of Health and Human Services issued its recommendation that cannabis be reclassified to Schedule III, from Schedule I.

Next step entails the DEA issuing a final decision regarding a reclassification.

- Recent Ohio legalization underscores Americans' support for the issue¹
- Continuing our work to ensure we are well positioned for the possibility of entering the US capital markets
- In the interim, we will do what we do best- keep our heads down and efficiently operate the business

THANK YOU

Julianna Paterra, CFA
VP, Investor Relations

Email

Investors@Verano.com

Website

Investors.Verano.com

VERANO[™]



APPENDIX

CORE MARKETS

ILLINOIS, FLORIDA, ARIZONA, NEW JERSEY,
PENNSYLVANIA, NEVADA, MARYLAND,
CONNECTICUT, OHIO



IL



Market Overview

- Adult use and medical
- 12.6M population
- Adult use sales began in January 2020
- 130k medical patients; 1.5% penetration
- Total market expected to grow from \$1.9B (2022) to \$2.5B (2027E) in annual sales

Verano Operations

- 10 operational dispensaries
- 192k sq. ft. cultivation and manufacturing facility in Albion

VERANO[™]

FL



Market Overview

- Medical
- 22.3M population
- Medical sales began in September 2016
- 857k medical patients; 4.5% penetration
- Total market expected to grow from \$2.2B (2022) to \$4.3B (2027E) in annual sales

Verano Operations

- 74 operational dispensaries
- 220k sq. ft. cultivation and manufacturing facility in Apollo Beach
- 42k sq. ft. cultivation and manufacturing facility in Palatka with optionality for further expansion

Market size forecasts based on BDSA estimates. Patient counts based on BDSA estimates. Includes the contribution from the following: (1) licenses directly owned, managed, or operated; (2) those licenses with which Verano has executed management agreements or other commercial agreements

43

AZ



Market Overview

- Adult use and medical
- 7.4M population
- Adult use sales began in January 2021
- 115k medical patients; 2.4% penetration
- Total market expected to grow from \$1.3B (2022) to \$1.6B (2027E) in annual sales

Verano Operations

- 6 operational dispensaries
- 42k sq. ft. cultivation and manufacturing facility in Coolidge
- 20K sq. ft. cultivation and manufacturing facility in Winslow

NJ



Market Overview

- Adult use and medical
- 9.2M population
- Adult use sales began in April 2022
- 102k medical patients; 1.7% penetration
- Total market expected to grow from \$593M (2022) to \$2.7B (2027E) in annual sales

Verano Operations

- 3 operational dispensaries
- 120k sq. ft. cultivation and manufacturing facility in Branchburg

PA



Market Overview

- Medical
- 12.9M population
- Medical sales began in February 2018
- 435k medical patients; 0.5% penetration
- Total market expected to grow from \$1.1B (2022) to \$1.8B (2027E) in annual sales

Verano Operations

- 18 operational dispensaries; 1 additional opening planned
- 62k sq. ft. cultivation and manufacturing facility in Chester
- Additional cultivation and manufacturing facility in Upland

NV



Market Overview

- Adult use and medical
- 3.3M population
- Adult use sales began in July 2017
- 12k medical patients; 0.5% penetration
- Total market expected to grow from \$866M (2022) to \$1.0B (2027E) in annual sales

Verano Operations

- 5 operational dispensaries
- 42k sq. ft. cultivation and manufacturing facility in North Las Vegas

MD



Market Overview

- Medical
- 6.2M population
- Adult use sales approved to begin July 1, 2023
- 170k medical patients; 3.5% penetration
- Total market expected to grow from \$491M (2022) to \$1.3B (2027E) in annual sales

Verano Operations

- 4 operational dispensaries
- 39k sq. ft. cultivation and manufacturing facility in Jessup

CT



Market Overview

- Adult use and Medical
- 3.6M population
- Adult use sales began in January 2023
- 45k medical patients; 1.8% penetration
- Total market expected to grow from \$157M (2022) to \$799M (2027E) in annual sales

Verano Operations

- 4 operational dispensaries, 2 of which are through social equity JVs; 4 additional openings planned
- 217k sq. ft. cultivation and manufacturing facility in Rocky Hill

OH



Market Overview

- Medical
- 11.8M population
- Medical sales began in January 2019
- 338k medical patients; 3.7% penetration
- Total market expected to grow from \$479M (2022) to \$1.6B (2027E) in annual sales

Verano Operations

- 5 operational dispensaries
- 22k sq. ft. cultivation and manufacturing facility in Canton



Market size forecasts based on BDSA estimates. Patient counts based on BDSA estimates. Includes the contribution from the following: (1) licenses directly owned, managed, or operated; (2) those licenses with which Verano has executed management agreements or other commercial agreements

VERANO[™]

DEVELOPING MARKETS

MASSACHUSETTS

MICHIGAN

WEST VIRGINIA

ARKANSAS



MA



Market Overview

- Adult use and medical
- 7.0M population
- Adult use sales began in November 2018
- 92k medical patients; 1.8% penetration
- Total market expected to grow from \$1.7B (2022) to \$1.9B (2027E) in annual sales

Verano Operations

- 2 operational dispensaries
- 26k sq. ft. cultivation and manufacturing facility in Sharon

MI



Market Overview

- Adult use and medical
- 10.0M population
- Adult use sales began in December 2019
- 162k medical patients; 2.5% penetration
- Total market expected to grow from \$2.3B (2022) to \$3.5B (2027E) in annual sales

Verano Operations

- 1 operational dispensary

WV



Market Overview

- Medical
- 1.8M population
- Medical sales began in November 2021
- 26k medical patients; 1.2% penetration
- Total market expected to grow from \$24M (2022) to \$84M (2027E) in annual sales

Verano Operations

- 5 operational dispensaries; option to open 2 more
- 40k sq. ft. cultivation and manufacturing facility in Beaver

AR



Market Overview

- Medical
- 3.1M population
- Medical sales began in May 2019
- 99k medical patients; 4.1% penetration
- Total market expected to grow from \$227M (2022) to 249M (2027E) in annual sales

Verano Operations

- 1 operational dispensary

Market size forecasts based on BDSA estimates. Patient counts based on BDSA estimates. Includes the contribution from the following: (1) licenses directly owned, managed, or operated; (2) those licenses with which Verano has executed management agreements or other commercial agreements

FINANCIAL APPENDIX



VERANO HOLDINGS CORP.
Highlights from Unaudited Interim Condensed Consolidated Statements of Operations
(\$ in Thousands)

	For the Three Months Ended,		
	September 30, 2023	June 30, 2023	September 30, 2022
Revenues, net of Discounts	\$ 240,088	\$ 234,115	\$ 227,588
Cost of Goods Sold, net	106,868	118,924	104,594
Gross Profit	133,220	115,191	122,994
Gross Profit %	55 %	49 %	54 %
Operating Expenses			
Selling, General and Administrative	86,316	84,660	85,710
Loss on Impairment - Investment in Associates	6,571	—	—
Total Operating Expenses	92,887	84,660	85,710
Loss from Investments in Associates	(45)	(101)	(209)
Income from Operations	40,288	30,430	37,075
Other Income (Expense):			
Gain (Loss) on Disposal of Property, Plant and Equipment	(234)	(388)	1,443
Gain on Deconsolidation	—	—	75
Gain on Previously Held Equity Interest	—	—	175
Interest Expense, net	(15,166)	(14,013)	(11,785)
Other Income (Expense), net	2,145	(1,411)	(595)
Total Other Income (Expense), Net	(13,255)	(15,812)	(10,687)
Income Before Provision for Income Taxes and Non-Controlling Interest	27,033	14,618	26,388
Provision for Income Tax Expense	(44,797)	(27,679)	(69,381)
Net Income Attributable To Non-Controlling Interest	78	—	—
Net Loss Attributable to Verano Holdings Corp. & Subsidiaries	(17,842)	(13,061)	(42,993)

VERANO HOLDINGS CORP.
Highlights from Condensed Consolidated Balance Sheets
(\$ in Thousands)

	September 30,	December 31,
	2023	2022
	<i>(Unaudited)</i>	
Cash and Cash Equivalents	\$ 129,921	\$ 84,851
Other Current Assets	225,083	233,424
Property and Equipment, Net	512,589	525,905
Intangible Assets, Net	1,114,088	1,180,766
Goodwill	269,222	269,088
Other Long-Term Assets	104,200	102,021
Total Assets	\$ 2,355,103	\$ 2,396,055
Total Current Liabilities	\$ 352,300	\$ 386,645
Total Long-Term Liabilities	689,318	667,860
Total Shareholders' Equity	1,313,407	1,341,550
Non-Controlling Interest	78	—
Total Liabilities and Shareholders' Equity	\$ 2,355,103	\$ 2,396,055

VERANO HOLDINGS CORP.
Free Cash Flow Guidance Reconciliation (Non-U.S. GAAP)

	Full-Year 2023 Guidance	
	Low	High
<i>(\$ in thousands)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Net Cash Provided by Operating Activities	\$ 102,000	\$ 113,000
Purchase of property, plant, and equipment	(30,000)	(37,000)
Free Cash Flow	\$ 72,000	\$ 76,000

VERANO HOLDINGS CORP.
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Non-U.S. GAAP)

	Nine Months Ended September 30,	
	2023	2022
<i>(\$ in thousands)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Net Cash Provided by Operating Activities	\$ 77,361	\$ 65,311
Purchase of property, plant, and equipment	(26,503)	(109,720)
Free Cash Flow	\$ 50,858	\$ (44,409)

	Three Months Ended September 30,	
	2023	
<i>(\$ in thousands)</i>	<i>(Unaudited)</i>	
Net Cash Provided by Operating Activities	\$ 36,621	
Purchase of property, plant, and equipment	(9,962)	
Free Cash Flow	\$ 26,659	

VERANO HOLDINGS CORP.
Reconciliation of Net Loss to EBITDA (Non-U.S. GAAP)

	For the Three Months Ended,		For the Nine Months Ended,	
	September 30, 2023	September 30, 2022	September 30, 2023	September 30, 2022
<i>(\$ in thousands)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Net Loss Attributable to Verano Holdings Corp. & Subsidiaries	\$ (17,842)	\$ (42,993)	\$ (40,140)	\$ (53,054)
Interest Expense, Net	15,166	11,785	45,084	34,082
Income Tax Expense	44,797	69,381	100,796	105,998
Depreciation and Amortization - COGS	18,384	20,727	55,434	59,540
Depreciation and Amortization - SG&A	16,882	15,592	50,125	46,690
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)	\$ 77,387	\$ 74,492	\$ 211,299	\$ 193,256

VERANO HOLDINGS CORP.
Reconciliation of Net Loss to EBIT (Non-U.S. GAAP) and Adjusted EBITDA (Non-U.S. GAAP)

	For the Three Months Ended,		
	September 30, 2023	June 30, 2023	September 30, 2022
<i>(\$ in thousands)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Net Loss Attributable to Verano Holdings Corp. & Subsidiaries	\$ (17,842)	\$ (13,061)	\$ (42,993)
Interest Expense, Net	15,166	14,013	11,785
Income Tax Expense	44,797	27,679	69,381
Earnings Before Interest, Taxes (EBIT)	\$ 42,121	\$ 28,631	\$ 38,173
COGS Add-backs:			
Depreciation and Amortization - COGS	18,384	18,529	20,727
Acquisition, Transaction and Other Non-operating Costs	—	—	111
Employee Stock Compensation	625	488	1,745
SG&A Add-backs:			
Depreciation and Amortization - SG&A	16,882	16,708	15,592
Acquisition, Transaction and Other Non-operating Costs	617	472	(1,791)
Employee Stock Compensation	4,062	3,260	8,075
Acquisition Adjustments and Other Income (Expense), net	\$ 6,658	\$ 3,424	\$ (508)
Adjusted EBITDA	\$ 89,349	\$ 71,512	\$ 82,124